552-02 ( DrugBank: - )

---

2 diseases

ID	Disease name (Link within this page)	Number of trials
53	Sjogren syndrome	1
299	Cystic fibrosis	1

53. Sjogren syndrome

---

Clinical trials : 283 /  Drugs : 320 - (DrugBank : 101) / Drug target genes : 56 - Drug target pathways : 181

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00852839 (ClinicalTrials.gov)	February 2009	26/2/2009	A Safety and Efficacy Study of 552-02 in Subjects With Dry Mouth Associated With Sjogren's Syndrome	A Randomized, Double-Blind, Vehicle-Controlled, Parallel Arm Study of 552-02 in Subjects With Dry Mouth Associated With Sjogren's Syndrome	Dry Mouth Associated With Sjogren's Syndrome;Xerostomia	Drug: Placebo;Drug: 552-02	Parion Sciences	NULL	Completed	18 Years	80 Years	All	140	Phase 2	United States

299. Cystic fibrosis

---

Clinical trials : 1,696 /  Drugs : 1,644 - (DrugBank : 272) / Drug target genes : 96 - Drug target pathways : 170

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00274313 (ClinicalTrials.gov)	January 2006	6/1/2006	Safety Study of Inhaled 552-02 in Cystic Fibrosis Patients	A Study of the Safety and Pharmacokinetics of 552-02 Following 14 Days of Dosing By Inhalation in Patients With Cystic Fibrosis	Cystic Fibrosis	Drug: 552-02	Parion Sciences	NULL	Completed	14 Years	N/A	Both	40	Phase 1/Phase 2	United States